MetaCap

Compass Therapeutics (CMPX) vs Fate Therapeutics (FATE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Compass Therapeutics (CMPX) over the past year, losing 10.8% versus a loss of 85.9%. Over five years, CMPX leads with a -78.6% price change compared with -98.3% for FATE. Compass Therapeutics is the larger company by market cap ($123.9 million vs $111.8 million), about 1.1 times the size, while Fate Therapeutics is growing revenue faster (-51.2% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CMPX-85.87%FATE-10.78%
+216%+57%-102%
Nov 21, 20251 yearNov 20, 2026
CMPX-80.22%FATE-98.36%
+97%-6%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CMPX versus FATE key metrics
MetricCMPXFATE
Share price$0.6882$0.919
Market cap$123.94M$111.82M
1-day change+1.43%-9.01%
YTD return-87.18%-6.22%
1-year return-85.87%-10.78%
5-year return-78.63%-98.25%
EPS (TTM)$-0.46$-1.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$6.65M
Revenue growth (YoY)-100.00%-51.24%
Net income (latest FY)$-66.49M$-136.31M
Operating margin—-2222.45%
Net margin—-2051.08%
52-week high$6.88$3.23
52-week low$0.57$0.90
Distance from 52-week high-90.00%-71.55%
Analyst consensusbuybuy
Avg. price target upside+664.31%+522.42%
Average volume3.88M1.53M
Shares outstanding180.09M121.67M
Employees39161
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed CMPX by 75.1 percentage points over the past year.
  • Fate Therapeutics grew revenue faster in its latest fiscal year (-51.24% vs -100.00%).

About Compass Therapeutics

CMPX stock →

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

CMPX vs FATE FAQ

Which is bigger, Compass Therapeutics or Fate Therapeutics?

Compass Therapeutics (CMPX) is larger, with a market capitalization of $123.94M compared with $111.82M for Fate Therapeutics (FATE).

Which stock has performed better over the past year, CMPX or FATE?

FATE returned -10.78% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.

Are Compass Therapeutics and Fate Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons